The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.

Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.

Karen will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.

The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.

The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for MDMA using Catalent’s proprietary Zydis® ODT technology.

Reporting to Julien Meissonnier, Catalent’s Vice President, and Chief Scientific Officer, Dr. Ling will join the company’s Science & Technology Leadership team.

The acquisition strengthens capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs.

Xenetic Biosciences today announced it has entered into a manufacturing agreement with Catalent, which will include cGMP manufacturing for the recombinant protein, Human DNase I.

Catalent’s new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.